NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
IGM Biosciences, Inc.
Novartis
Biosplice Therapeutics, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Eisai Inc.
Mereo BioPharma
Zhejiang University
AB Science
Bionomics Limited
CR-CSSS Champlain-Charles-Le Moyne
Pfizer
EMD Serono